Organisation
Liver Connexin and Pannexin Research Group
Research Group
The research topic of LCPR is the study of the use of connexins and pannexins as drug targets and biomarkers for the therapy and diagnosis of acute and chronic liver disease.
Projects
1 - 7 of 7
- H2020: Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessmentFrom1 May 2021 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Cellular communication as target and biomarker in liver disease and toxicity: from basic research towards clinical applicationFrom1 Jan 2021 → TodayFunding: BOF - Methusalem
- Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases.From1 Mar 2020 → TodayFunding: H2020-EU.1.2.- EXCELLENT SCIENCE - Future and Emerging Technologies (FET)
- GEAR: Brussels Liver Research to Valorisation Alliance (B-Liver): Valorisation of VUB’s liver cell biology and toxicology expertise via a consortium focused on liver therapeutics, patient and consumer safety.From1 Jan 2020 → TodayFunding: IOF - technology concept exploration, IOF - mandates
- CONNECT-2-CLINIC: Connexin and pannexin peptidomimetics and nanobodies for the clinical treatment of liver disease.From1 Jan 2020 → 31 Dec 2021Funding: H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
- Connexin hemichannels and pannexin channels as mediators and in vitro indicators of drug-induced cholestatic liver injury.From1 Nov 2019 → 31 Oct 2023Funding: FWO fellowships
- Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer? (Toekenning in het kader van bilaterale onderzoekssamenwerking met Brazilië)From1 Jan 2019 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 98
- Development and characterization of a new human hepatic cell line(2015)
Authors: Eva Ramboer, Bram De Craene, Geert Berx, Vera Rogiers, Tamara Vanhaecke, Mathieu Vinken
Pages: 875-889 - Methods in Molecular Biology volume 1981: Experimental Cholestasis Research(2019)
Authors: Mathieu Vinken
Number of pages: 399 - Challenging the predictive power and robustness of an adverse outcome pathway construct from bile salt export pump inhibition to cholestatic liver injury(2015)Volume: 5
Authors: Mathieu Vinken, Vera Rogiers
Pages: 75-76Number of pages: 2 - In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist(2018)
Authors: Mathieu Vinken
Pages: 1909-1912 - Adverse outcome pathway development from protein alkylation to liver fibrosis(2017)
Authors: Tomislav Horvat, Brigitte Landesmann, Alfonso Lostia, Mathieu Vinken, Sharon Munn, Maurice Whelan
Pages: 1523-1543 - An update on adverse outcome pathways leading to liver injury(2017)
Authors: Mathieu Vinken
Pages: 283-285 - Protocols in In Vitro Hepatocyte Research(2015)Series: Methods in Molecular Biology
Authors: Mathieu Vinken, Vera Rogiers
Number of pages: 285 - Measurement of apoptotic and necrotic cell death in primary hepatocyte cultures(2015)Series: Methods in Molecular BiologyVolume: 1250
Authors: Michael Maes, Tamara Vanhaecke, Bruno Cogliati, Sara Crespo Yanguas, Joost Willebrords, Vera Rogiers, Mathieu Vinken
Pages: 349-361Number of pages: 12 - Characterizing the coverage of critical effects relevant in the safety evaluation of food additives by AOPs(2019)
Authors: Nynke Kramer, Yvette Hoffmans, Siyao Wu, Anette Thiel, Natalie Thatcher, Timothy Allen, Sara Levorato, Heinz Traussnig, Stefan Schulte, Alan Boobis, et al.
Pages: 2115-2125 - Connexins, pannexins and their channels in fibroproliferative diseases(2016)
Authors: Bruno Cogliati, Gregory Mennecier, Joost Willebrords, Tereza Cristina da Silva, Michael Maes, Isabel Veloso Alves Pereira, Sara Crespo Yanguas, Francisco Hernandez-Blazquez, Maria Lucia Zaidan Dagli, Mathieu Vinken
Pages: 199-213